Using topical TLR7 agonist imiquimod in patients with skin metastases from breast cancer showed 20% partial response with histologic tumor regression with changes in tumor lymphocytic infiltrate and local cytokines profile [102]. This evidence concerns the gene TLR7 and neoplasm.